This Article Full Text Full Text (PDF) CME: Take the course for this article: Advances in the Management of Acute Promyelocytic Leukemia and Other Hemato... eLetters: Submit a response to this article Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Slack, J. L. Articles by Bloomfield, C. D. Search for Related Content PubMed PubMed Citation Articles by Slack, J. L. Articles by Bloomfield, C. D.

Advances in the Management of Acute Promyelocytic Leukemia and Other Hematologic Malignancies with Arsenic Trioxide

^a Departments of Hematologic Oncology and Bone Marrow Transplantation, Roswell Park Cancer Institute, Buffalo, New York, USA; ^b Rochelle Belfer Chemotherapy Foundation Laboratory, Mt. Sinai School of Medicine, New York, New York, USA; ^c Myeloma and Transplantation Research Center, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA; ^d Northwestern University Medical School, Chicago, Illinois, USA; ^e The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, USA

Clara D. Bloomfield, M.D., 320 W. 10th Avenue, A455 Starling Loving Hall, Columbus, Ohio 43210, USA. Telephone: 614-293-7518; Fax: 614-293-7520; e-mail: bloomfield-1{at}medctr.osu.edu

Acute promyelocytic leukemia (APL), once considered the most devastating subtype of acute myeloid leukemia, is now the most treatable of all subtypes as a result of intensive research into its molecular pathogenesis. This research has led to a rational approach to treatment in which the use of the differentiating agent all-trans-retinoic acid (ATRA) has proven to be effective first-line treatment for inducing complete remission. Arsenic trioxide (ATO) is currently used to treat relapsed disease, further enhancing survival rates in a patient population for which limited salvage options exist. This review discusses the molecular mechanisms responsible for development of APL and the evolution of treatment options over the last three decades, including the major advances using ATRA and ATO in the last 12 years. The mechanism of action of ATO is also described in view of this agent's potential for broader therapeutic application in a variety of hematologic malignancies.

Key Words. Acute promyelocytic leukemia • All-trans-retinoic acid • Arsenic trioxide • Hematologic malignancy • Multiple myeloma

This article has been cited by other articles:

				S. Ghaffari, S Rostami, D Bashash, K Alimoghaddam, and A Ghavamzadeh Real-time PCR analysis of PML-RAR{alpha} in newly diagnosed acute promyelocytic leukaemia patients treated with arsenic trioxide as a front-line therapy Ann. Onc., October 1, 2006; 17(10): 1553 - 1559. [Abstract] [Full Text] [PDF]

				M. F. Aguero, M. M. Facchinetti, Z. Sheleg, and A. M. Senderowicz Phenoxodiol, a Novel Isoflavone, Induces G1 Arrest by Specific Loss in Cyclin-Dependent Kinase 2 Activity by p53-Independent Induction of p21WAF1/CIP1 Cancer Res., April 15, 2005; 65(8): 3364 - 3373. [Abstract] [Full Text] [PDF]

				G. Pruneri, L. Pignataro, S. Valentini, S. Fabris, P. Maisonneuve, N. Carboni, S. Pece, M. Capra, B. Del Curto, A. Neri, et al. Cyclin D3 Immunoreactivity Is an Independent Predictor of Survival in Laryngeal Squamous Cell Carcinoma Clin. Cancer Res., January 1, 2005; 11(1): 242 - 248. [Abstract] [Full Text] [PDF]

				L.-H. Yih and T.-C. Lee Induction of C-Anaphase and Diplochromosome through Dysregulation of Spindle Assembly Checkpoint by Sodium Arsenite in Human Fibroblasts Cancer Res., October 15, 2003; 63(20): 6680 - 6688. [Abstract] [Full Text] [PDF]